Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more
Amicogen Inc (092040) - Total Liabilities
Latest total liabilities as of September 2025: ₩139.22 Billion KRW
Based on the latest financial reports, Amicogen Inc (092040) has total liabilities worth ₩139.22 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amicogen Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Amicogen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amicogen Inc Competitors by Total Liabilities
The table below lists competitors of Amicogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Los Andes Copper Ltd
OTCQX:LSANF
|
USA | $24.03 Million |
|
Yangarra Resources Ltd
PINK:YGRAF
|
USA | $290.53 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
Thailand | ฿1.92 Billion |
|
D0X
F:D0X
|
Germany | €164.00K |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
Turkey | TL3.74 Billion |
|
Auburn National Bancorporation Inc
NASDAQ:AUBN
|
USA | $-89.61 Million |
|
1S90
F:1S90
|
Germany | €99.78 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Amicogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amicogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amicogen Inc (2014–2024)
The table below shows the annual total liabilities of Amicogen Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩171.73 Billion | -30.79% |
| 2023-12-31 | ₩248.12 Billion | -16.70% |
| 2022-12-31 | ₩297.86 Billion | +32.34% |
| 2021-12-31 | ₩225.06 Billion | +72.56% |
| 2020-12-31 | ₩130.43 Billion | +9.28% |
| 2019-12-31 | ₩119.35 Billion | +14.84% |
| 2018-12-31 | ₩103.93 Billion | +39.83% |
| 2017-12-31 | ₩74.32 Billion | +14.71% |
| 2016-12-31 | ₩64.79 Billion | -16.65% |
| 2015-12-31 | ₩77.74 Billion | +1688.10% |
| 2014-12-31 | ₩4.35 Billion | -- |